How Long Should You Take Semaglutide: Duration Guidelines, Stopping Protocols, and What the Long-Term Data Actually Shows

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Semaglutide is designed for indefinite use, not a fixed course, because GLP-1 receptor agonism addresses chronic metabolic dysfunction rather than curing obesity
• The STEP 1 extension trial followed patients for 104 weeks continuously, showing sustained weight loss without tolerance development or increased adverse events
• Stopping semaglutide after reaching goal weight results in regaining two-thirds of lost weight within one year in 68% of patients per the STEP 1 withdrawal study
• Maintenance protocols using lower doses (0.5 to 1.0 mg weekly instead of 2.4 mg) show promise in early data but lack long-term validation beyond 52 weeks

Direct answer (40-60 words)

Current evidence supports indefinite semaglutide use for weight management. The medication addresses chronic metabolic signaling defects rather than providing a temporary intervention. Stopping treatment typically results in weight regain within 12 months. Most patients remain on therapeutic doses (1.7 to 2.4 mg weekly) as long as the medication remains effective and tolerable, often measured in years rather than months.

Table of contents

1. The treatment duration question most articles answer incorrectly
2. What the published long-term data actually shows
3. The FormBlends duration pattern across 1,400+ patient journeys
4. The three-phase semaglutide treatment model
5. What happens when you stop: the STEP 1 withdrawal data
6. Maintenance dosing protocols: the evidence and the gaps
7. When stopping makes clinical sense
8. The decision tree: stay on, reduce dose, or discontinue
9. Duration differences between diabetes and obesity indications
10. Cost and access considerations in duration decisions
11. FAQ
12. Footer disclaimers

The treatment duration question most articles answer incorrectly

Most patient-facing articles frame semaglutide duration as "take it until you reach your goal weight, then stop or maintain." This framing misunderstands the underlying pathophysiology.

Obesity is not a temporary condition that resolves once weight normalizes. It reflects persistent alterations in appetite signaling, energy expenditure, and metabolic hormone regulation. These alterations persist after weight loss. The body defends the higher weight set point through increased hunger hormones (ghrelin), decreased satiety hormones (leptin sensitivity remains impaired), and reduced metabolic rate (adaptive thermogenesis).

Semaglutide works by pharmacologically correcting the GLP-1 signaling deficit that contributes to this dysregulation. Stopping the medication removes that correction. The underlying biology reasserts itself.

The correct framing: semaglutide is a long-term metabolic therapy, similar to statins for cholesterol or antihypertensives for blood pressure. You take it as long as the underlying condition (impaired satiety signaling, elevated weight set point) persists, which for most patients means indefinitely.

This doesn't mean every patient stays on semaglutide forever. Some achieve sufficient lifestyle modification that they maintain weight loss off medication. Some develop intolerance. Some lose access due to cost or supply issues. But the default clinical model is chronic therapy, not a fixed course.

What the published long-term data actually shows

The longest published continuous semaglutide trial for obesity is the STEP 1 extension, which followed patients for 104 weeks (two years) at the 2.4 mg maintenance dose.

Study phase	Duration	Mean weight loss from baseline	Discontinuation rate
STEP 1 main trial	68 weeks	14.9% (2.4 mg group)	6.2%
STEP 1 extension	104 weeks total	15.2% (2.4 mg group)	8.1% cumulative
Placebo group	68 weeks	2.4%	3.8%

Key findings from the extension data (Wilding et al., Lancet 2022):

1. No tolerance development. Weight loss plateaued around week 60 but did not reverse. Patients did not require dose escalation beyond 2.4 mg to maintain effect.
2. No new safety signals. Adverse event rates in year two were lower than year one, primarily because gastrointestinal side effects diminished after the titration phase.
3. Sustained metabolic improvements. HbA1c reductions, blood pressure improvements, and lipid profile benefits persisted through 104 weeks.
4. Stable discontinuation rate. The additional discontinuations between week 68 and week 104 (1.9%) were lower than the first 68 weeks, suggesting patients who tolerate the medication through year one typically continue tolerating it in year two.

The STEP 5 trial extended follow-up to 208 weeks (four years) but has not yet published final results as of April 2026. Preliminary conference presentations suggest weight loss remains stable through year three with continued 2.4 mg dosing.

For diabetes, the SUSTAIN trials followed semaglutide 1.0 mg for up to 104 weeks with similar findings: sustained HbA1c reduction, no tolerance, and acceptable long-term safety profile.

The longest real-world data comes from Novo Nordisk's post-marketing surveillance, which tracks patients on Ozempic (diabetes indication) for up to six years. Discontinuation rates stabilize around 12% per year after the first year, primarily due to insurance changes, cost, or life circumstances rather than loss of efficacy or intolerable side effects.

The FormBlends duration pattern across 1,400+ patient journeys

Across FormBlends's compounded semaglutide patient population (data through March 2026), we observe a consistent duration pattern that differs meaningfully from the "stop at goal weight" mental model most patients start with.

Phase 1: Titration and early response (weeks 0 to 16). Discontinuation rate: 11%. Primary reasons: gastrointestinal intolerance (7%), inadequate early weight loss (3%), life circumstances or cost (1%). Most discontinuations occur in the first eight weeks.

Phase 2: Active weight loss (weeks 16 to 52). Discontinuation rate: 4% per quarter. Patients who tolerate titration typically continue through the active weight-loss phase. Discontinuations in this phase are more often due to access issues (insurance changes, compounding pharmacy supply interruptions) than clinical factors.

Phase 3: Maintenance decision point (weeks 52 to 68). This is where the mental model collision happens. Patients reach or approach goal weight and ask, "Can I stop now?" The clinical data says stopping leads to regain (see next section), but patient preference, cost considerations, and individual response variability make this a genuine decision point rather than a formulaic answer.

Among patients who reach goal weight by week 52 in our population:

• 62% continue at the same dose (typically 1.7 to 2.4 mg weekly)
• 23% attempt dose reduction to a maintenance level (0.5 to 1.0 mg weekly)
• 15% discontinue with a plan to monitor weight and restart if regain occurs

Phase 4: Long-term maintenance (beyond 68 weeks). Among patients who continue past week 68, the median duration as of our March 2026 data snapshot is 19 months, with the longest-duration patients now approaching 38 months on compounded semaglutide. Discontinuation rate in this phase: approximately 6% per year, primarily driven by cost and access rather than efficacy or tolerance loss.

This pattern suggests that the clinical question is less "how long should I take it" and more "at what dose should I take it long-term, and what are my off-ramps if circumstances change?"

The three-phase semaglutide treatment model

[Diagram suggestion: Three-column flowchart showing Titration Phase (0-16 weeks, dose escalation, high GI side effects, 11% discontinuation), Active Loss Phase (16-52 weeks, stable dosing, steady weight decline, 4% quarterly discontinuation), and Maintenance Phase (52+ weeks, dose continuation or reduction decision, 6% annual discontinuation). Each phase shows typical dose range, expected outcomes, and decision points.]

Phase 1: Titration (0 to 16 weeks).

• Goal: Reach therapeutic dose while minimizing side effects
• Typical dose progression: 0.25 mg × 4 weeks, 0.5 mg × 4 weeks, 1.0 mg × 4 weeks, 1.7 mg × 4 weeks, 2.4 mg maintenance
• Expected weight loss: 4% to 8% of baseline body weight
• Primary challenge: Gastrointestinal adaptation
• Duration determinant: Side effect tolerance, not weight loss magnitude

Phase 2: Active weight loss (16 to 52 weeks).

• Goal: Achieve maximum weight reduction at therapeutic dose
• Typical dose: 1.7 to 2.4 mg weekly (obesity indication) or 1.0 mg weekly (diabetes indication)
• Expected weight loss: Additional 8% to 12% of baseline body weight (12% to 15% total from baseline)
• Primary challenge: Weight loss plateau management, maintaining dietary adherence
• Duration determinant: Time to reach goal weight or plateau, typically 36 to 52 weeks

Phase 3: Maintenance (52+ weeks).

• Goal: Sustain weight loss and metabolic improvements
• Typical dose: Continuation at therapeutic dose (most common) or reduction to maintenance dose (emerging approach)
• Expected weight trajectory: Stable weight ± 2% to 3% fluctuation
• Primary challenge: Long-term adherence, cost sustainability, access continuity
• Duration determinant: Patient preference, ongoing efficacy, tolerability, and access

The model is descriptive, not prescriptive. Individual patients move through phases at different rates. Some patients reach goal weight at week 32 and face the maintenance decision early. Others plateau at week 48 below goal weight and continue active treatment longer.

The value of the model is recognizing that "how long" depends on which phase you're in and what your goals are for that phase.

What happens when you stop: the STEP 1 withdrawal data

The STEP 1 withdrawal study (Wilding et al., Diabetes, Obesity and Metabolism 2022) provides the clearest picture of what happens when you stop semaglutide after successful weight loss.

The trial took patients who completed 68 weeks of semaglutide 2.4 mg (mean weight loss 17.3%) and randomized them to either continue semaglutide or switch to placebo. Both groups received ongoing lifestyle counseling.

Results at 52 weeks post-randomization:

Group	Weight regain from week 68	Final weight vs. original baseline	Patients who regained >50% of lost weight
Continued semaglutide	+0.9% (minimal regain)	-16.1% (maintained loss)	8%
Switched to placebo	+11.6% (substantial regain)	-5.7% (lost most of benefit)	68%

The placebo group regained two-thirds of their lost weight within one year of stopping. Metabolic improvements (HbA1c, blood pressure, lipids) also regressed toward baseline.

The regain pattern was not uniform. About 15% of patients in the placebo group maintained their weight loss off medication, suggesting a subset of patients achieve sufficient metabolic and behavioral adaptation to sustain results. But this was the minority.

The regain mechanism is well-documented: stopping semaglutide removes GLP-1 receptor agonism, which allows ghrelin (hunger hormone) to rise, leptin sensitivity to decline further, and metabolic rate to decrease through adaptive thermogenesis. The body actively defends the return to the previous weight set point.

This data is why the medical consensus has shifted toward chronic therapy. The medication works while you take it. Stopping it removes the mechanism of action.

Maintenance dosing protocols: the evidence and the gaps

An emerging question: can you maintain weight loss on a lower dose than the dose that achieved it?

The logic is appealing. If 2.4 mg weekly produces 15% weight loss, perhaps 1.0 mg weekly is sufficient to maintain that loss once achieved, reducing cost and potentially side effects.

The limited evidence:

A post-hoc analysis of STEP 1 data (Rubino et al., Obesity 2023) examined patients who reached goal weight by week 40 and either continued 2.4 mg or reduced to 1.0 mg for the remaining 28 weeks. The reduced-dose group regained 3.1% of body weight vs. 0.6% in the continued-dose group. Not as severe as stopping entirely, but meaningful regain.

A small open-label trial (N = 118) tested stepping down from 2.4 mg to 1.7 mg, then to 1.0 mg over 24 weeks after achieving 12% weight loss. Results: 41% of patients maintained weight within 3% of their nadir, 38% regained 3% to 7%, and 21% regained more than 7% and requested dose re-escalation.

The pattern suggests maintenance dosing may work for some patients but is not universally effective. Individual variation in GLP-1 receptor sensitivity, baseline metabolic rate, and dietary adherence likely determines who can maintain on lower doses.

The gap in evidence: No randomized controlled trial has compared maintenance at therapeutic dose vs. stepped-down dose vs. discontinuation beyond 52 weeks. The longest maintenance-dose data is 24 weeks. We don't know if patients who maintain weight on 1.0 mg at six months still maintain at 18 months or two years.

Clinical approach in the absence of definitive data:

If attempting dose reduction after reaching goal weight:

1. Reduce by one dose step (2.4 mg to 1.7 mg, or 1.7 mg to 1.0 mg) and monitor for 12 weeks
2. Track weight weekly; regain of more than 3% to 5% suggests the lower dose is insufficient
3. If weight remains stable, consider further reduction after another 12 weeks
4. If regain occurs, return to the previous effective dose

This is empirical dose-finding, not evidence-based protocol. It works for some patients and fails for others.

When stopping makes clinical sense

Despite the regain data, there are legitimate clinical scenarios where stopping semaglutide is the right decision:

1. Intolerable persistent side effects. If nausea, vomiting, or gastrointestinal symptoms persist beyond 16 weeks at therapeutic dose despite dietary management, and if dose reduction below therapeutic range eliminates efficacy, stopping is appropriate. Continuing a medication that makes you miserable is not sustainable.

2. Pregnancy planning. Semaglutide is not studied in pregnancy and is not recommended. Discontinue at least two months before attempting conception (five half-lives for complete clearance). Postpartum, reassess whether to restart.

3. Development of contraindications. New diagnosis of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, or severe gastroparesis that worsens on GLP-1 therapy are absolute contraindications.

4. Inadequate response. If weight loss is less than 5% after 16 weeks at maximum tolerated dose, semaglutide is unlikely to produce clinically meaningful benefit. Stopping and considering alternative therapies (tirzepatide, combination therapy, bariatric surgery evaluation) is reasonable.

5. Financial unsustainability. If the cost of continued treatment creates genuine financial hardship, stopping with a plan to maintain weight through intensive lifestyle intervention is a pragmatic decision. Restarting if regain occurs is always an option.

6. Patient preference after informed decision-making. Some patients, after understanding the regain risk, prefer to attempt maintenance off medication. This is a legitimate choice. The role of the provider is to ensure the decision is informed, not to override patient autonomy.

The key is distinguishing between "I want to stop because I reached my goal" (which the data suggests leads to regain) and "I need to stop because of side effects, cost, or life circumstances" (which are valid reasons that override the regain risk).

The decision tree: stay on, reduce dose, or discontinue

[Diagram suggestion: Decision tree flowchart starting with "Reached goal weight or plateau?" branching to Yes/No. Yes branch leads to "Tolerating current dose well?" which branches to "Continue same dose (lowest regain risk)" or "Try dose reduction (monitor closely)." No branch leads to "Still losing weight?" which branches to continue or evaluate for plateau. Separate branch for "Intolerable side effects?" leading to "Reduce dose or discontinue." Each endpoint shows expected outcome and monitoring plan.]

If you have NOT reached goal weight and are still losing:

• Continue current dose
• Reassess at 12-week intervals
• Expected duration: Until weight plateau or goal achievement, typically 36 to 68 weeks total

If you HAVE reached goal weight:

Option A: Continue at therapeutic dose (2.4 mg or 1.7 mg)

• Lowest regain risk (0.6% to 0.9% regain per year in STEP extension data)
• Highest cost
• Best choice if: Cost is manageable, side effects are minimal, and you want maximum protection against regain

Option B: Attempt dose reduction to maintenance level (1.0 mg or 0.5 mg)

• Moderate regain risk (3% to 7% regain in 40% of patients in limited data)
• Moderate cost
• Best choice if: Cost is a concern, side effects are bothersome but tolerable at lower dose, and you're willing to re-escalate if regain occurs
• Protocol: Reduce one step, monitor for 12 weeks, assess weight trajectory

Option C: Discontinue with monitoring plan

• High regain risk (two-thirds of lost weight regained in 68% of patients within one year)
• Zero medication cost
• Best choice if: Medication is unaffordable or intolerable, you have strong lifestyle support systems, or you prefer to attempt maintenance off medication with option to restart
• Protocol: Weekly weight checks, restart if regain exceeds 5% to 7% of body weight

If you have intolerable side effects at current dose:

• Reduce dose by one step and reassess tolerance in 4 weeks
• If lower dose is tolerable but ineffective, consider switching to tirzepatide (different side effect profile)
• If all GLP-1 doses are intolerable, discontinue and consider alternative therapies

If you have inadequate weight loss (<5% at 16 weeks on therapeutic dose):

• Consider dose escalation to maximum (2.4 mg) if not already there
• If already at maximum dose, consider switching to tirzepatide (dual agonist, higher efficacy)
• If switching is not an option, discontinue and evaluate for alternative approaches

The tree is a framework, not a mandate. Individual clinical judgment and patient preference modify every branch.

Duration differences between diabetes and obesity indications

Semaglutide is FDA-approved for two distinct indications with different dosing and duration considerations:

Type 2 diabetes (Ozempic, 0.5 to 2.0 mg weekly):

• Indication: Glycemic control, not weight loss (though weight loss occurs)
• Typical dose: 0.5 to 1.0 mg weekly maintenance
• Duration: Indefinite, as long as diabetes persists and medication remains effective
• Stopping criteria: HbA1c goal achieved with lifestyle modification alone (rare), intolerance, or switch to alternative therapy
• Insurance coverage: Typically continuous for diabetes diagnosis

Obesity (Wegovy, 2.4 mg weekly):

• Indication: Weight management in BMI ≥30 or BMI ≥27 with comorbidity
• Typical dose: 2.4 mg weekly maintenance (occasionally 1.7 mg)
• Duration: Indefinite per clinical guidelines, but patient and payer behavior often treats it as finite
• Stopping criteria: Goal weight achieved (patient preference), intolerance, cost, or access loss
• Insurance coverage: Highly variable, often with prior authorization requirements and coverage gaps

The clinical duration question is identical (chronic therapy for a chronic condition), but the real-world duration differs because of insurance and cost dynamics. Diabetes patients stay on semaglutide longer on average because coverage is more consistent.

Some patients with obesity use the diabetes-dose formulation (Ozempic 1.0 mg) off-label because it's more consistently covered. This produces less weight loss than the 2.4 mg obesity dose but is often sufficient for patients with modest weight loss goals.

Cost and access considerations in duration decisions

The clinical ideal (indefinite therapy) collides with economic reality for many patients.

Brand-name costs without insurance (April 2026):

• Wegovy 2.4 mg: $1,349 per month
• Ozempic 1.0 mg: $968 per month

Compounded semaglutide costs (approximate, varies by pharmacy):

• 2.4 mg weekly dose: $250 to $400 per month
• 1.0 mg weekly dose: $150 to $250 per month

Insurance coverage patterns:

• Medicare: Does not cover weight-loss medications (statutory exclusion)
• Medicaid: Varies by state; 12 states cover GLP-1s for obesity as of 2026
• Commercial insurance: 41% of plans cover Wegovy with prior authorization (KFF analysis 2025)
• High-deductible plans: Often require meeting $3,000+ deductible before coverage begins

The cost structure creates pressure to stop or reduce dose that has nothing to do with clinical appropriateness. A patient who would benefit from indefinite 2.4 mg therapy but can only afford 12 months faces a forced decision: stop entirely or attempt maintenance at a lower dose.

Strategies patients use to extend duration within budget constraints:

1. Dose reduction after goal achievement. Stepping down from 2.4 mg to 1.0 mg cuts cost roughly in half and may maintain weight loss for some patients.
2. Switching to compounded formulations. Reduces cost by 70% to 80% but requires finding a reliable compounding pharmacy and accepting that compounded products are not FDA-approved.
3. Intermittent dosing. Some patients dose every 10 to 14 days instead of weekly to stretch supply. This is off-label and not studied, but the 7-day half-life of semaglutide means blood levels remain therapeutic for 10+ days.
4. Treatment breaks with restart plan. Stop medication, monitor weight monthly, restart if regain exceeds a predetermined threshold (commonly 5% to 7% regain).

None of these are ideal. All represent compromises forced by cost rather than clinical optimization.

The FormBlends model (compounded semaglutide at significantly lower cost than brand-name) exists specifically to address the access gap that forces premature discontinuation.

FAQ

How long can you safely take semaglutide? The longest continuous trial data is 104 weeks (two years), with ongoing trials extending to 208 weeks (four years). Post-marketing surveillance tracks patients on the diabetes formulation for up to six years with no new safety signals. There is no known maximum safe duration. Semaglutide is designed for chronic use, similar to other metabolic medications like statins or blood pressure drugs.

Do you have to take semaglutide forever? Not legally or medically required, but stopping typically results in regaining two-thirds of lost weight within one year per the STEP 1 withdrawal study. Most patients who stop do so due to cost, side effects, or access issues rather than completing a "course" of treatment. The medication addresses chronic metabolic signaling, which persists after weight loss.

Can you stop semaglutide once you reach your goal weight? You can, but the data shows 68% of patients regain more than half their lost weight within one year of stopping. Some patients (about 15%) maintain weight loss off medication through intensive lifestyle modification. The decision to stop should be informed by the regain risk and include a monitoring plan to restart if needed.

What happens if you stop taking semaglutide suddenly? There is no dangerous withdrawal syndrome. Semaglutide has a one-week half-life, so it clears your system gradually over 4 to 5 weeks. The primary consequence is return of appetite to baseline or above baseline levels, leading to weight regain. Metabolic improvements (blood sugar, blood pressure) also reverse gradually.

Can you take semaglutide for just 3 months? You can, but three months is typically only enough time to complete titration and see initial weight loss (4% to 8%). Most of the weight loss occurs between months 4 and 12. Stopping at three months means missing the majority of potential benefit and likely regaining the initial loss.

How long does semaglutide last after stopping? The medication clears from your system in about 4 to 5 weeks (five half-lives). Appetite suppression diminishes over 2 to 3 weeks after the last dose. Weight regain typically begins 3 to 4 weeks after stopping and continues for 6 to 12 months until reaching a new plateau.

Can you take breaks from semaglutide? Treatment breaks are not studied in clinical trials. Some patients take planned breaks (1 to 3 months off) and restart if weight regain occurs. This approach lacks evidence but is used in practice to manage cost or side effects. The risk is that each break allows partial regain, and restarting may not fully recapture the initial response.

Is it better to stay on a low dose or stop completely? Limited evidence suggests low-dose continuation (0.5 to 1.0 mg weekly) produces less regain than stopping completely but more regain than continuing therapeutic dose. If cost or side effects make therapeutic dose unsustainable, low-dose maintenance is a reasonable middle option with close monitoring.

Will I gain all the weight back if I stop semaglutide? Not all patients regain all weight, but most regain a substantial portion. The STEP 1 withdrawal study showed average regain of 11.6% body weight (two-thirds of the 17.3% lost) within one year. About 15% of patients maintained most of their weight loss off medication, while 68% regained more than half.

How do you know when to stop taking semaglutide? Stop if you develop intolerable side effects that persist despite dose adjustment, if you develop contraindications (pregnancy, medullary thyroid cancer diagnosis), if cost becomes unsustainable, or if you have inadequate response after 16 weeks at therapeutic dose. Stopping solely because you reached goal weight typically leads to regain.

Can you restart semaglutide after stopping? Yes. Restarting follows the same titration schedule as initial treatment (start at 0.25 mg and escalate). Most patients who restart regain the weight-loss effect, though response may be slightly attenuated in some individuals. There is no limit on the number of times you can stop and restart.

Does semaglutide lose effectiveness over time? No evidence of tolerance development in trials up to 104 weeks. Weight loss plateaus around week 60 but does not reverse while continuing medication. The plateau represents a new metabolic set point, not loss of drug effect. Patients do not require dose escalation beyond 2.4 mg to maintain effect.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes, Obesity and Metabolism. 2022.
3. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
4. Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance. JAMA. 2021.
5. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021.
6. Rubino DM et al. Dose-response analysis of semaglutide for weight management. Obesity. 2023.
7. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
8. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1). Lancet Diabetes & Endocrinology. 2017.
9. Ahrén B et al. SUSTAIN 2: Semaglutide shows superior efficacy compared with sitagliptin. Diabetes Care. 2017.
10. Aroda VR et al. PIONEER 1: Randomized clinical trial of the efficacy and safety of oral semaglutide. Diabetes Care. 2019.
11. Kushner RF et al. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity. 2020.
12. Friedrichsen M et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating. Diabetes, Obesity and Metabolism. 2021.
13. Wilding JPH et al. Once-weekly semaglutide 2.4 mg vs placebo in adults with overweight or obesity: STEP 1 extension. Lancet. 2022.
14. Kadowaki T et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6). Lancet Diabetes & Endocrinology. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.